Novo Nordisk announced that the FDA has approved NovoLog (insulin aspart [rDNA origin] injection) FlexTouch and Levemir (insulin detemir [rDNA origin] injection) FlexTouch, its two new prefilled insulin delivery systems.

RELATED: Endocrine Disorders Resource Center

When a dose is dialed with traditional prefilled pens, the push button extends, and at larger doses this can present challenges for the patient. The dosing mechanism of FlexTouch ensures the push-button does not extend at any dose and allows insulin to be administered by pressing the low dose force button.

NovoLog FlexTouch contains 300 units of insulin aspart and Levemir FlexTouch contains 300 units of insulin detemir (long-acting). Both pens dose in 1 unit increments, from 1–80 units, and are compatible with both NovoFine and NovoTwist needles. 

NovoLog and Levemir are man-made insulins used to control high blood sugar in adults and children with diabetes mellitus.

NovoLog FlexTouch and Levemir FlexTouch are anticipated to be available within the next year.

For more information call (800) 727-6500 or visit